NMDA Archives - Gateway Psychiatric Excellent Psychiatric Care Wed, 07 Jul 2021 13:28:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://i0.wp.com/www.gatewaypsychiatric.com/wp-content/uploads/2013/06/favicon2.png?fit=32%2C32&ssl=1 NMDA Archives - Gateway Psychiatric 32 32 70562394 A Better Ketamine https://www.gatewaypsychiatric.com/a-better-ketamine/ Mon, 13 Jun 2016 20:37:40 +0000 https://www.gatewaypsychiatric.com/?p=10981 A better ketamine may be coming. That is the conclusion of NEJM Journal Watch Psychiatry reviewer Barbara Geller. A common pathway to identifying new drugs, is looking at metabolites of a medication to see if there is one metabolite that works better than the active drug (desvenlafaxine – one of the metabolites of venlafaxine – may or may not be ...

The post A Better Ketamine appeared first on Gateway Psychiatric.

]]> 10981 Rapastinel for Depression https://www.gatewaypsychiatric.com/rapastinel-for-depression/ Wed, 10 Feb 2016 18:55:30 +0000 https://www.gatewaypsychiatric.com/?p=9902 The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to rapastinel, which follows the medication receiving a 2014 Fast Track Designation from the FDA. Rapastinel, an investigational medication for adjunctive treatment of major depressive disorder, is an intravenous drug that is a novel NMDA receptor agonist. It is being developed by Allergan. The Breakthrough Therapy designation is a new ...

The post Rapastinel for Depression appeared first on Gateway Psychiatric.

]]> 9902 Ketamine for Depression Update https://www.gatewaypsychiatric.com/ketamine-for-depression-update/ Sun, 04 Oct 2015 16:32:29 +0000 https://www.gatewaypsychiatric.com/?p=9261 Probably the most exciting development in psychopharmacology in years is the discovery of the dramatic effects of ketamine on depression. However, a recent report from the American Psychiatric Association (APA) Task Force on Novel Biomarkers and Treatments highlights not only the reason for the excitement about ketamine but also the significant areas of uncertainty that make it not yet ready to ...

The post Ketamine for Depression Update appeared first on Gateway Psychiatric.

]]> 9261 NMDA Receptor and Depression https://www.gatewaypsychiatric.com/nmda-receptor-depression/ Fri, 06 Feb 2015 14:38:38 +0000 https://www.gatewaypsychiatric.com/?p=8863 A new drug that stimulates the glycine site of NMDA receptors had rapid antidepressant effects in the just released results of a phase II clinical trial. The drug substantially reduced depression symptoms, with no severe side effects. The NMDA receptor has 2 sites that are involved in its activation. One site is stimulated by glutamate or aspartate. Another site is stimulated by glycine. For ...

The post NMDA Receptor and Depression appeared first on Gateway Psychiatric.

]]> 8863 Ketamine for Depression – Mechanism of Action https://www.gatewaypsychiatric.com/ketamine-depression-mechanism-action/ Sat, 04 Oct 2014 16:15:42 +0000 https://www.gatewaypsychiatric.com/?p=8187 Ketamine for Depression: How does it work? We ran across a useful review of the basic science literature in an interview of David Nichols on the Psych Congress Network. http://www.psychcongress.com/video/ketamine-quick-guide-receptors-19116 Although ketamine blocks the NMDA subtype of glutamate receptors (blocks an excitatory neurotransmitter) the net effect seems to be an increase in excitatory neurotransmission. This image from Nature may help ...

The post Ketamine for Depression – Mechanism of Action appeared first on Gateway Psychiatric.

]]> 8187